Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curazink is a small molecule pharmaceutical product containing zinc histidine, a complex of the essential trace element zinc and the amino acid L-histidine. While it is an established treatment for zinc deficiency conditions, it is currently being investigated for its potential anti-inflammatory and neuroprotective effects in patients with mild cognitive impairment (MCI) or mild Alzheimer's disease. The drug's mechanism of action is hypothesized to involve the modulation of the TGF-β1 signaling pathway, which leads to an increase in immunosuppressive cytokines such as TGF-β1 and IL-10, and the promotion of regulatory T cell (Treg) activity. This approach aims to mitigate the neuroinflammation associated with the progression of Alzheimer's dementia. In clinical studies, it is administered orally as a hard capsule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc histidine.